HSA
GLUE icon

Hussman Strategic Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Hussman Strategic Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,000
Closed -$1.04M – 268
2026
Q1 		$1.04M Buy
+63,000
New +$1.2M 0.22% 186

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hussman Strategic Advisors's GLUE Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 63,000 shares — an estimated $1.04M sold.

Hussman Strategic Advisors first reported a position in GLUE in Q1 2026 and held it in 1 quarter. The position peaked at $1.04M in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 63,000 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.04M.
  • Hussman Strategic Advisors first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 1 quarter.
  • Hussman Strategic Advisors's Monte Rosa Therapeutics position peaked at $1.04M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.